Pembrolizumab, a humanized immunoglobulin G4 antibody directed against programmed cell death protein 1 (PD-1), has been approved by FDA in mismatch repair deficient (MMR-D) solid tumors, including pancreatic cancer[6]. Here, PDCD1 is linked to hyperinsulinemic hypoglycemia, familial, 4.